Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 3/20 | 0.60 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | MGMT | P16455 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059711 | 0.79 | MGMT (0.47) | CDC7DBF4LMNATSHRALDH1A1 | |
| SCHEMBL6431905 | 0.78 | LTA4H (0.44) | CDC7DBF4LMNAMAPK1HTT | |
| SCHEMBL4063841 | 0.78 | PIN1 (0.63) | CDC7DBF4LMNATSHRL3MBTL1 | |
| SCHEMBL1404475 | 0.75 | CDC7 (1.00) | CDC7DBF4LMNATSHRALDH1A1 | |
| SCHEMBL16432196 | 0.75 | TRPA1 (0.55) | TSHRDYRK1AL3MBTL1MAP3K7TAB1 | |
| SCHEMBL29178671 | 0.73 | DYRK1A (0.46) | CDC7DBF4DYRK1AMAP3K7TAB1 | |
| SCHEMBL15612939 | 0.73 | DYRK1A (0.53) | MAPK1DYRK1AEGFRTTBK1TTBK2 | |
| SCHEMBL21968803 | 0.72 | POLB (0.50) | CDC7DBF4LMNATSHRHPGD | |
| SCHEMBL17042730 | 0.72 | CDC7 (0.56) | CDC7DBF4LMNATSHRALDH1A1 | |
| SCHEMBL4544686 | 0.71 | LMNA (0.61) | LMNATSHRHPGDMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021083438-A1 | INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE - SYNTHESIS AND USE THEREOF FOR TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOMA | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V. V. I. (CZ) | 2021-05-06 | — | — | WO | disclosed |
| WO-2012150866-A1 | PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-11-08 | — | — | WO | disclosed |
| CN-101062928-B | Process for preparing 2-pyrrolidinyl-1h-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside metabolism | IND RES LTD | 2010-10-06 | — | — | CN | disclosed |
| US-20090247750-A1 | PROCESS FOR PREPARING NUCLEOSIDE ANALOGS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009082247-A1 | PROCESS FOR PREPARING IMMUCILLINS HAVING A METHYLENE LINK | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-07-02 | — | — | WO | disclosed |
| CN-101062928-A | Process for preparing 2-pyrrolidinyl-1h-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside metabolism | IND RES LTD (NZ) | 2007-10-31 | — | — | CN | disclosed |
| CN-100344630-C | 3H, 5H-pyrrolo [3, 2-d ] pyrimidin-4-one derivatives and process for producing the same | IND RES LTD (NZ) | 2007-10-24 | — | — | CN | disclosed |
| CN-1727341-A | 3H, 5H-pyrrolo [3, 2-d ] pyrimidin-4-one derivatives and process for producing the same | IND RES LTD (NZ) | 2006-02-01 | — | — | CN | disclosed |
| CN-1196704-C | Process for preparing nucleoside metabolism inhibitor and intermediate compound | IND RES LTD (NZ) | 2005-04-13 | — | — | CN | disclosed |
| CN-1370171-A | Process for preparing nucleoside metabolism inhibitors | IND RES LTD (NZ) | 2002-09-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247750-A1 | PROCESS FOR PREPARING NUCLEOSIDE ANALOGS | PNP, TYMP, UMPS | CDC7 677/4885DBF4 1047/4885LMNA 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.